Wall Street Zen Downgrades Ralliant (NYSE:RAL) to Hold

Ralliant (NYSE:RAL) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Several other analysts have also recently issued reports on RAL. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Truist Financial reaffirmed a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Morgan Stanley increased their price objective on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a report on Tuesday. Citigroup lifted their price objective on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Finally, Barclays boosted their target price on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Trading Down 1.8%

NYSE:RAL opened at $72.24 on Friday. The company has a fifty day moving average of $58.13 and a 200 day moving average of $51.25. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $8.09 billion and a P/E ratio of -6.60.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, research analysts predict that Ralliant will post 2.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Viking Global Investors LP purchased a new position in shares of Ralliant in the 2nd quarter valued at approximately $257,200,000. State Street Corp bought a new position in shares of Ralliant in the 2nd quarter worth about $213,096,000. Millennium Management LLC increased its stake in shares of Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares in the last quarter. Norges Bank purchased a new stake in Ralliant in the fourth quarter worth about $124,687,000. Finally, Invesco Ltd. grew its stake in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after buying an additional 1,835,128 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.